(Q48758870)

15 February 2018

title

Bipap improves survival and rate of pulmonary function decline in patients with ALS. (English)

1 reference

15 February 2018

amyotrophic lateral sclerosis

main subject

1 reference

Kleopa KA

1

1 reference

15 February 2018

Sherman M

2

1 reference

15 February 2018

Neal B

3

1 reference

15 February 2018

Romano GJ

4

1 reference

15 February 2018

Heiman-Patterson T

5

1 reference

15 February 2018

publication date

1 March 1999

1 reference

15 February 2018

Journal of the Neurological Sciences

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

15 February 2018

volume

164

1 reference

15 February 2018

issue

1

1 reference

15 February 2018

page(s)

82-88

1 reference

15 February 2018

The natural history of motoneuron loss in amyotrophic lateral sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

The natural history of amyotrophic lateral sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Effects of alterations in pulmonary function and sleep variables on survival in patients with amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Pulmonary function at diagnosis of amyotrophic lateral sclerosis. Rate of deterioration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Spirometry in Amyotrophic Lateral Sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family, and physician attitudes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation. Advance care planning and outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

7 January 2021

Noninvasive ventilation

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Ventilatory muscle support in respiratory failure with nasal positive pressure ventilation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Night-time nasal ventilation in neuromuscular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Noninvasive face mask mechanical ventilation in patients with acute hypercapnic respiratory failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Review of respiratory care of the patient with amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Randomised trial of preventive nasal ventilation in Duchenne muscular dystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Natural history of ALS: symptoms, strength, pulmonary function, and disability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Diaphragmatic fatigue in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Exhaustive exercise, endurance training, and acid hydrolase activity in skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Sustained reversal of chronic hypercapnia in patients with alveolar hypoventilation syndromes. Long-term maintenance with noninvasive nocturnal mechanical ventilation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Efficacy of Nocturnal Nasal Ventilation in Patients with Restrictive Thoracic Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Management of ALS: respiratory care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

Issues in clinical trial design I: Use of natural history controls. A protagonist view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900045-3

10.1016/S0022-510X(99)00045-3

7 January 2021

Identifiers

DOI

1 reference

15 February 2018

1 reference

15 February 2018